A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers

Hisao Asamura, Tomoyuki Goya, Yoshihiko Koshiishi, Yasunori Sohara, Kenji Eguchi, Masaki Mori, Yohichi Nakanishi, Ryosuke Tsuchiya, Kaoru Shimokata, Hiroshi Inoue, Toshihiro Nukiwa, Etsuo Miyaoka

Research output: Contribution to journalArticle

307 Citations (Scopus)

Abstract

PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer. METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry. The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics. RESULTS: The 5-year survival rate of the entire group was 61.4%. For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13). For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV. Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors. CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer. The prognostic difference between stages IB and IIA was small despite different stages. Otherwise, the present tumor, node, metastasis staging system well characterizes the stage-specific prognoses.

Original languageEnglish
Pages (from-to)46-52
Number of pages7
JournalJournal of Thoracic Oncology
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Registries
Lung Neoplasms
Histology
Survival Rate
Neoplasm Metastasis
Benchmarking
Lung
Neoplasms
Adenocarcinoma
Carcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Asamura, H., Goya, T., Koshiishi, Y., Sohara, Y., Eguchi, K., Mori, M., ... Miyaoka, E. (2008). A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers. Journal of Thoracic Oncology, 3(1), 46-52. https://doi.org/10.1097/JTO.0b013e31815e8577

A Japanese lung cancer registry study : Prognosis of 13,010 resected lung cancers. / Asamura, Hisao; Goya, Tomoyuki; Koshiishi, Yoshihiko; Sohara, Yasunori; Eguchi, Kenji; Mori, Masaki; Nakanishi, Yohichi; Tsuchiya, Ryosuke; Shimokata, Kaoru; Inoue, Hiroshi; Nukiwa, Toshihiro; Miyaoka, Etsuo.

In: Journal of Thoracic Oncology, Vol. 3, No. 1, 01.2008, p. 46-52.

Research output: Contribution to journalArticle

Asamura, H, Goya, T, Koshiishi, Y, Sohara, Y, Eguchi, K, Mori, M, Nakanishi, Y, Tsuchiya, R, Shimokata, K, Inoue, H, Nukiwa, T & Miyaoka, E 2008, 'A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers', Journal of Thoracic Oncology, vol. 3, no. 1, pp. 46-52. https://doi.org/10.1097/JTO.0b013e31815e8577
Asamura, Hisao ; Goya, Tomoyuki ; Koshiishi, Yoshihiko ; Sohara, Yasunori ; Eguchi, Kenji ; Mori, Masaki ; Nakanishi, Yohichi ; Tsuchiya, Ryosuke ; Shimokata, Kaoru ; Inoue, Hiroshi ; Nukiwa, Toshihiro ; Miyaoka, Etsuo. / A Japanese lung cancer registry study : Prognosis of 13,010 resected lung cancers. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 1. pp. 46-52.
@article{3964c738b8e44b9a903ca5a0a78dbb6b,
title = "A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers",
abstract = "PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer. METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry. The data of 13,010 patients with only lung carcinoma histology (97.6{\%}) were analyzed in terms of prognosis and clinicopathologic characteristics. RESULTS: The 5-year survival rate of the entire group was 61.4{\%}. For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8{\%} (n = 161) and 58.3{\%} (n = 127) for IA, 58.0{\%} (n = 77) and 60.2{\%} (n = 79) for IB, 47.1{\%} (n = 17) and 40.6{\%} (n = 29) for IIA, 25.3{\%} (n = 38) and 41.1{\%} (n = 29) for IIB, 29.0{\%} (n = 61) and 28.3{\%} (n = 60) for IIIA, 36.3{\%} (n = 19) and 34.6{\%} (n = 40) for IIIB, and 27.8{\%} (n = 12) and 30.8{\%} for IV (n = 13). For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3{\%} (n = 5642) and 83.9{\%} (n = 4772) for IA, 59.8{\%} (n = 3081) and 66.3{\%} (n = 2629) for IB, 54.1{\%} (n = 205) and 61.0{\%} (n = 361) for IIA, 43.9{\%} (n = 1227) and 47.4{\%} (n = 1330) for IIB, 38.3{\%} (n = 1628) and 32.8{\%} (n = 1862) for IIIA, 32.6{\%} (n = 526) and 29.6{\%} (n = 1108) for IIIB, and 26.5{\%} (n = 198) and 23.1{\%} (n = 375) for IV. Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors. CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer. The prognostic difference between stages IB and IIA was small despite different stages. Otherwise, the present tumor, node, metastasis staging system well characterizes the stage-specific prognoses.",
author = "Hisao Asamura and Tomoyuki Goya and Yoshihiko Koshiishi and Yasunori Sohara and Kenji Eguchi and Masaki Mori and Yohichi Nakanishi and Ryosuke Tsuchiya and Kaoru Shimokata and Hiroshi Inoue and Toshihiro Nukiwa and Etsuo Miyaoka",
year = "2008",
month = "1",
doi = "10.1097/JTO.0b013e31815e8577",
language = "English",
volume = "3",
pages = "46--52",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - A Japanese lung cancer registry study

T2 - Prognosis of 13,010 resected lung cancers

AU - Asamura, Hisao

AU - Goya, Tomoyuki

AU - Koshiishi, Yoshihiko

AU - Sohara, Yasunori

AU - Eguchi, Kenji

AU - Mori, Masaki

AU - Nakanishi, Yohichi

AU - Tsuchiya, Ryosuke

AU - Shimokata, Kaoru

AU - Inoue, Hiroshi

AU - Nukiwa, Toshihiro

AU - Miyaoka, Etsuo

PY - 2008/1

Y1 - 2008/1

N2 - PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer. METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry. The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics. RESULTS: The 5-year survival rate of the entire group was 61.4%. For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13). For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV. Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors. CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer. The prognostic difference between stages IB and IIA was small despite different stages. Otherwise, the present tumor, node, metastasis staging system well characterizes the stage-specific prognoses.

AB - PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer. METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry. The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics. RESULTS: The 5-year survival rate of the entire group was 61.4%. For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13). For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV. Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors. CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer. The prognostic difference between stages IB and IIA was small despite different stages. Otherwise, the present tumor, node, metastasis staging system well characterizes the stage-specific prognoses.

UR - http://www.scopus.com/inward/record.url?scp=37549050198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549050198&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31815e8577

DO - 10.1097/JTO.0b013e31815e8577

M3 - Article

C2 - 18166840

AN - SCOPUS:37549050198

VL - 3

SP - 46

EP - 52

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -